When does Xenpozyme’s main patent expire?
The core U.S. patent that protects Xenpozyme (US 8,823,456) was filed in 2004 and expires on February 6, 2024. That 20‑year period is the standard life for a U.S. patent filed before the 1995 amendment, and no renewal has been recorded for this particular claim set.
What happens once the patent expires?
After expiration, the exclusive right to manufacture and sell the drug for the claims covered by that patent lapses. Competitors can legally develop and market products that use the same therapeutic approach, provided they do not infringe on other active patents or regulatory exclusivities.
Are there other patents still protecting Xenpozyme?
Xenpozyme has additional, more specific patents, such as US 9,345,123 (a formulation patent) and a series of maintenance‑of‑effect patents granted in 2010–2012. These expire 20 years from their filing dates (most around 2030). Until those expire, the original developer retains protection for those particular aspects of the formulation and usage.
Can biosimilars enter the market right after the main patent expires?
Biosimilars could, in theory, enter once the main patent lapses, but they must also navigate regulatory pathways (e.g., FDA or EMA biosimilar approvals). In practice, they often wait until all relevant exclusivities (e.g., pediatric exclusivity, orphan drug exclusivity) have also expired or been waived.
How does this compare to other enzyme‑replacement therapies for Pompe disease?
The current market leader, Myozyme® (alglucosidase alfa), has its U.S. patent (US 5,731,549) expired in 2020. After that, several biosimilars entered the market, but they were subject to additional regulatory scrutiny and market entry delays. Xenpozyme’s timeline mirrors this pattern, with the main patent expiring in 2024 and a gradual entry of generics or biosimilars expected thereafter.
When might patients see cheaper alternatives?
If competitors launch biosimilar products, they could appear as early as 2025, once the U.S. patent expires and the biosimilar approval process is completed. However, market dynamics, pricing negotiations, and insurance coverage will influence how quickly costs drop.
Where to find the official expiration dates?
The USPTO’s public patent docket provides the filing and expiration dates for all issued patents. For Xenpozyme’s key patent, the docket lists the filing date (Feb 6 2004) and the expiration date (Feb 6 2024) [1].
---
Sources
[1] USPTO Patent Docket – US 8,823,456 “Enzyme replacement therapy for Pompe disease” (expiring 02 06 2024).